EXEL·Exelixis Inc.

BMO Capital’s analyst David Lebowitz has just initiated coverage on Exelixis, giving the stock a Market Perform rating and a $54 price target, a move that signals renewed confidence in the company’s oncology pipeline after recent clinical data. The rating implies that BMO expects steady revenue growth and potential upside from upcoming product approvals, which should lift the stock’s valuation over the next 1–10 trading days. Investors will want to see the company’s Q2 2026 earnings confirm these expectations, particularly any updates on clinical milestones that could support the new target. The Q2 2026 earnings call transcript, released 198 hours ago, provides context on revenue trends, R&D spending, and regulatory developments but does not offer new guidance. This lack of forward guidance means the market will rely heavily on the BMO rating and the company’s historical performance to gauge near‑term direction. A further development from 341 hours ago shows Exelixis cut its 2026 revenue outlook amid an oncology investment pivot, raising concerns about its growth trajectory. The downgrade suggests that the company may face challenges in achieving projected sales from its pipeline, which could temper enthusiasm for the BMO target. In the coming days, watch for any updates on clinical milestones or regulatory approvals that could offset the revenue shortfall, as well as any strategic moves such as divestitures or new product launches that might restore confidence in the company’s growth prospects.